Metraipolis › archive › dc_7de4331b1cb1

Systemic activation of NRF2 contributes to the therapeutic efficacy of clinically-approved KRAS-G12C anti-cancer drugs — Europe PMC PMID:40890297

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40890297
DOI
10.1038/s41416-[numero omesso]-7
License (as archived)
solo-consultazione
Archived
2026-11-10T05:13:54.333Z
SHA-256 of the archived text
e3c8b1880f250567a22f49eb927a72a42bd70a4aff49deb0d6875aa27a0e49ec
Stable URL of this page
https://metraipolis.com/documento/dc_7de4331b1cb1

How to cite

Systemic activation of NRF2 contributes to the therapeutic efficacy of clinically-approved KRAS-G12C anti-cancer drugs — Europe PMC PMID:40890297 — Europe PMC (en), https://europepmc.org/article/MED/40890297 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7de4331b1cb1 (Metraipolis archive dc_7de4331b1cb1, sha256 e3c8b1880f250567a22f49eb927a72a42bd70a4aff49deb0d6875aa27a0e49ec)
BibTeX
@misc{dc7de4331b1cb1,
  title = {Systemic activation of NRF2 contributes to the therapeutic efficacy of clinically-approved KRAS-G12C anti-cancer drugs — Europe PMC PMID:40890297},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40890297},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7de4331b1cb1; sha256 e3c8b1880f250567a22f49eb927a72a42bd70a4aff49deb0d6875aa27a0e49ec},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40890297. Agents can read the archived copy with the MCP tool read_document.